2-(4-Aminobenzo[d]isoxazol-3-yl)propan-2-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: 2-(4-Aminobenzo[d]isoxazol-3-yl)propan-2-ol
• 英文别名: 2-(4-amino-1,2-benzoxazol-3-yl)propan-2-ol
• 化学式: C₁₀H₁₂N₂O₂
• 分子量: 192.21
• InChiKey: BBQHZYABHBXWEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION<br/>[FR] NOUVEAUX PIÈGES DANS LE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE
  申请人：ALDEXA THERAPEUTICS INC

  公开号：WO2014116593A1

  公开（公告）日：2014-07-31

  The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.

  本发明涉及式(A)化合物、药物组合物以及用于治疗、减轻或降低黄斑变性症状或风险的方法。
• ALDEHYDE CONJUGATES AND USES THEREOF
  申请人：Aldeyra Therapeutics, Inc.

  公开号：US20200246345A1

  公开（公告）日：2020-08-06

  The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

  本发明提供了化合物及其使用方法，用于治疗、预防和/或减少由醛毒性引起病理发生的疾病、紊乱或状况的风险，包括眼部疾病、皮肤疾病、与水泡剂引起的有害效应相关的状况，以及自身免疫、炎症、神经和心血管疾病，通过使用一种主要胺来清除有毒醛类化合物，如MDA和HNE。
• TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
  申请人：ALDEYRA THERAPEUTICS, INC.

  公开号：US20150335632A1

  公开（公告）日：2015-11-26

  The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

  本发明提供了一种使用初级胺清除有毒醛类物质，如MDA和HNE，以治疗、预防和/或减少涉及醛毒性的疾病、疾病和疾病的风险，包括眼部疾病、皮肤疾病、与水泡剂有害影响相关的疾病、自身免疫、炎症、神经和心血管疾病。
• NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION
  申请人：ALDEYRA THERAPEUTICS, INC.

  公开号：US20150344447A1

  公开（公告）日：2015-12-03

  The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.

  本发明涉及化合物(A)的公式，制药组合物以及治疗，减少症状或减少黄斑变性风险的使用方法。
• Toxic aldehyde related diseases and treatment
  申请人：Aldeyra Therapeutics, Inc.

  公开号：US10543181B2

  公开（公告）日：2020-01-28

  The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

  本发明通过使用伯胺清除有毒的醛，如 MDA 和 HNE，从而治疗、预防和/或降低醛毒性与发病机制有关的疾病、失调或病症的风险，包括眼部疾病、皮肤疾病、与起泡剂的伤害作用有关的病症，以及自身免疫性、炎症性、神经性和心血管疾病。